csirt@kutim:~/threat-intel/cve/CVE-2026-73194

Katalog CVE

CVSS 9.1 · Critical EPSS 0,49%

Kerentanan Out-of-bounds Write. Skor CVSS 3.1 9.1 (Critical) menurut CISA ADP.

Deskripsi (NVD)

DBI versions before 1.652 for Perl allow a heap out-of-bounds write via an unvalidated numeric placeholder that sets the binder counter in preparse. preparse reserves seven output bytes per input byte, the width of the longest ':p99999' expansion. The ':N' branch parses the number with `atoi(src)` and assigns it to the binder counter with no range check, so a statement containing ':2147483648' leaves the counter negative (-2147483648 with glibc, where atoi wraps). Each following '?' then expands through `sprintf(start, ":p%d", idx++)` to ':p-2147483648', 14 bytes with the terminating NUL where the buffer budgets 7. The placeholder limit added in 1.650 tests the counter against 99,999, which a negative counter passes. Any caller that preparses an untrusted statement into ':pN' style placeholders gets a heap out-of-bounds write that grows with the number of '?' marks following the poisoned placeholder. The '?' and '%s' return styles compare the parsed number against the expected sequence and error out, and are unaffected.

Rincian

Terbit di NVD
15 Agustus 2026
Terakhir diubah
28 Agustus 2026
Status NVD
Awaiting Analysis
CVSS 3.1
9.1 (Critical), sumber CISA ADP
CVSS:3.1/AV:N/AC:L/PR:N/UI:N/S:U/C:H/I:N/A:H · uraikan di kalkulator
Jenis kelemahan (CWE)
CWE-787: Out-of-bounds Write
CWE-1284: Improper Validation of Specified Quantity in Input
EPSS (30 hari)
0,49% peluang dieksploitasi; lebih tinggi dari 40,6% CVE lain

Produk dan versi terdampak

NVD belum mencantumkan data produk (CPE) untuk CVE ini. Produk yang terdampak biasanya disebut di deskripsi dan di advisory vendor pada daftar referensi.

Referensi dan perbaikan

Sumber: NVD · CVE.org · EPSS. Halaman ini disusun otomatis dari data tersebut; pembaruan terakhir 5 Okt 2026, 20:11 WITA. Kalau sistem di Perangkat Daerah memakai produk ini dan butuh bantuan, laporkan lewat kanal pelaporan.